Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?
Journal of Oncology Pharmacy Practice · 2023-10 · 29 (7) · 1619-1627
DOI: 10.1177/10781552221144280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 07.12.2022. Verfasst von Cristina Fernández-Cuerva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy Specialist, Hospital Regional Universitario de Málaga, , Málaga, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Real-world data are critical to demonstrate the reproducibility of evidence and external generalizability of randomized clinical trials. The purpose of this study was to assess real-world security profile and management of adverse events (AEs) presented with ribociclib for the treatment of HR + /HER2− metastatic breast cancer (MBC). Our secondary objective was to provide real-world effectiveness of this treatment (measured with progression-free survival (PFS)) and to confirm the hypothesis that dose reductions are not related with disease progression. Material and methods: Observational retrospective study evaluating all females with MBC treated with ribociclib. Study period: January 2017 to September 2019. Follow-up was done until November 2021. Response was assessed through the PFS according to RECIST1.1 and National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) was used to classify AEs.
Results
The most common AE was any grade neutropenia, documented in 37 of 53 patients (69.8%) during the course of treatment. By the end of the follow-up period, overall median PFS with ribociclib therapy was 27.3 months (95% confidence interval (CI) 20.8–71.8 months). In total, 50 patients (94.4%) initiated ribociclib at 600 mg dose, 28 patients (58%) required dose reductions. PFS of patients receiving ribociclib as first-line treatment was 28 (95% CI 15–41 months).
Conclusions
Our results from patients treated in real-world clinical settings indicate that ribociclib is safe and their AEs are manageable with active monitoring, temporal suspension of treatment and dose reduction. Furthermore, our results indicate that dose reduction of ribociclib is not associated with a loss of efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Pharmacy Specialist, Hospital Regional Universitario de Málaga, , Málaga, Spain.
- Hospital Pharmacy Specialist, Hospital Alto Guadalquivir de Andujar, , Jaén, Spain.
ORCID-Profile: Cristina Fernández-Cuerva
Zitieren
APA
Fernández-Cuerva, C., Chinchilla-Alarcón, T., & Alcaraz-Sánchez, J. J. (2023). Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?. Journal of Oncology Pharmacy Practice, 29(7), 1619-1627. https://doi.org/10.1177/10781552221144280
Vancouver
Fernández-Cuerva C, Chinchilla-Alarcón T, Alcaraz-Sánchez JJ. Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?. Journal of Oncology Pharmacy Practice. 2023;29(7):1619-1627. doi:10.1177/10781552221144280
BibTeX
@article{FernndezCuerva2023,
author = {Fernández-Cuerva, Cristina and Chinchilla-Alarcón, Teresa and Alcaraz-Sánchez, Juan José},
title = {Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?},
journal = {Journal of Oncology Pharmacy Practice},
year = {2023},
volume = {29},
number = {7},
pages = {1619--1627},
doi = {10.1177/10781552221144280}
}
EUVIMED